Quick Takeaways
- ACAD - ACADIA PHARMACEUTICALS INC has 19 insiders with reported activity on this page.
- Net insider value flow over the last year: -$3,122,349.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 19 Insiders of ACADIA PHARMACEUTICALS INC
- Symbol
- ACAD on Nasdaq
- Location
- San Diego, CA
What Changed
- Buy value: ; sell value: $3,122,349.
- Net share flow: -139,387.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$3,122,349.
Buys
$0
Shares: 0
Insiders: 0
Sells
$3,122,349
Shares: 139,387
Insiders: 8
Net
-$3,122,349
Shares: -139,387
Insiders: -8
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 38,936 | $0 | $852,740 | -$852,740 |
| 3-6 | 0 | 44,346 | $0 | $1,010,851 | -$1,010,851 |
| 6-9 | 0 | 27,098 | $0 | $678,312 | -$678,312 |
| 9-12 | 0 | 29,007 | $0 | $580,446 | -$580,446 |
ACADIA PHARMACEUTICALS INC executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director, 10%+ Owner | $688,336,586 | Mixed | 29 May 2025 | ||
| Stephen Davis | CEO, Director | $4,050,942 | Mixed | 16 Aug 2024 | ||
| Adams Catherine Owen | Chief Executive Officer, Director | $2,032,151 | -$249,932 | -11% | Mixed | 24 Mar 2026 |
| Srdjan R. Stankovic | President | $1,834,571 | Mixed | 19 Nov 2022 | ||
| Douglas J. Williamson | Executive VP, Research & Dev | $1,517,624 | Mixed | 10 Feb 2023 | ||
| Mark C. Schneyer | Evp, Chief Financial Officer | $1,473,149 | -$1,200,212 | -45% | Mixed | 05 Apr 2026 |
| Austin D. Kim | EVP,General Counsel, Secretary | $1,405,154 | Filing P/S | 06 Jan 2024 | ||
| Brendan Teehan | Evp, Coo, Head Of Commercial | $1,210,623 | Mixed | 17 Nov 2024 | ||
| Daniel B. Soland | Director | $927,091 | Mixed | 29 May 2025 | ||
| Elizabeth A. Garofalo | Director | $818,321 | -$41,560 | -4.8% | Mixed | 02 Sep 2025 |
| Jennifer J. Rhodes | Evp, Chief Legal Officer, Sec | $790,211 | -$245,022 | -24% | Mixed | 24 Mar 2026 |
| Edmund Harrigan | Director | $770,131 | Mixed | 29 May 2025 | ||
| Thomas Garner | EVP, Chief Commercial Officer | $762,703 | Mixed | 06 Mar 2026 | ||
| James Kihara | Principal Accounting Officer | $652,874 | -$270,889 | -29% | Mixed | 05 Apr 2026 |
| Elizabeth H.z. Thompson | EVP, Head of Research & Dev | $560,097 | -$73,749 | -12% | Mixed | 24 Mar 2026 |
| Laura Brege | Director | $487,785 | -$314,634 | -39% | Mixed | 04 Jun 2025 |
| Adora Ndu | Director | $432,529 | Mixed | 29 May 2025 | ||
| James M. Daly | Director | $249,397 | -$670,983 | -73% | Mixed | 10 Nov 2025 |
| Jonathan Poole | Director | Mixed | 03 Mar 2026 |
Top shareholders of ACADIA PHARMACEUTICALS INC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13D/G
3/4/5
13F
|
Julian C. Baker · Director, 10%+ Owner · Company |
25%
|
43,294,373
|
$1,162,886,859 | $0 | 24 Feb 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
12%
from 13D/G
|
20,755,452
|
$554,378,124 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
8.9%
|
15,153,957
|
$404,762,192 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
4.6%
|
7,910,733
|
$211,295,678 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
4.2%
from 13D/G
|
7,144,524
|
$190,830,236 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2%
|
3,377,311
|
$90,207,977 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
3,239,451
|
$86,539,034 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.7%
|
2,920,974
|
$78,018,583 | — | 31 Dec 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
1.5%
|
2,484,031
|
$66,348,468 | — | 31 Dec 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
1.3%
|
2,270,034
|
$60,632,608 | — | 31 Dec 2025 | |
| BRAIDWELL LP |
13F
|
Company |
1.2%
|
2,032,021
|
$54,275,281 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.92%
|
1,570,051
|
$41,936,063 | — | 31 Dec 2025 | |
| FRED ALGER MANAGEMENT, LLC |
13F
|
Company |
0.92%
|
1,559,962
|
$41,666,585 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.91%
|
1,547,103
|
$41,493,266 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.9%
|
1,532,596
|
$40,935,639 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
0.88%
|
1,507,527
|
$40,266,046 | — | 31 Dec 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.88%
|
1,502,617
|
$40,134,900 | — | 31 Dec 2025 | |
| Trails Edge Capital Partners, LP |
13F
|
Company |
0.83%
|
1,419,406
|
$37,912,334 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.8%
|
1,367,459
|
$36,524,830 | — | 31 Dec 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.76%
|
1,297,198
|
$34,648,159 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.73%
|
1,235,829
|
$33,008,994 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.72%
|
1,221,445
|
$32,624,796 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.71%
|
1,202,601
|
$32,121,473 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.69%
|
1,172,317
|
$31,312,587 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.67%
|
1,141,974
|
$30,502,170 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.66%
|
1,119,117
|
$29,891,615 | — | 31 Dec 2025 | |
| Rockefeller Capital Management L.P. |
13F
|
Company |
0.65%
|
1,113,040
|
$29,729,299 | — | 31 Dec 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.63%
|
1,072,483
|
$28,646,021 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.62%
|
1,057,527
|
$28,246,546 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.6%
|
1,026,785
|
$27,425,427 | — | 31 Dec 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.5%
|
850,000
|
$22,703,500 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.5%
|
847,961
|
$22,649,038 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.49%
|
828,594
|
$22,131,746 | — | 31 Dec 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.48%
|
811,197
|
$21,667,072 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.45%
|
769,392
|
$20,550,461 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.44%
|
751,985
|
$20,085,519 | — | 31 Dec 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.44%
|
745,356
|
$19,908,459 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.43%
|
726,963
|
$19,417,179 | — | 31 Dec 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.4%
|
681,102
|
$18,192,234 | — | 31 Dec 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.39%
|
665,087
|
$17,764,473 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.39%
|
662,241
|
$17,677,800 | — | 31 Dec 2025 | |
| Allspring Global Investments Holdings, LLC |
13F
|
Company |
0.39%
|
658,813
|
$17,320,194 | — | 31 Dec 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.38%
|
641,511
|
$17,134,758 | — | 31 Dec 2025 | |
| JUPITER ASSET MANAGEMENT LTD |
13F
|
Company |
0.36%
|
621,049
|
$16,588,219 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.36%
|
615,169
|
$16,432,000 | — | 31 Dec 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.36%
|
614,410
|
$16,411,000 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.35%
|
604,748
|
$16,152,819 | — | 31 Dec 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.35%
|
603,740
|
$16,125,895 | — | 31 Dec 2025 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.34%
|
580,969
|
$15,517,682 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.32%
|
553,674
|
$14,788,633 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for ACADIA PHARMACEUTICALS INC
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mark C. Schneyer | ACAD | Common Stock | Sale | -4.13% | $60,140 | $22.20 | -2,709 | 62,836 | 07 Apr 2026 | Direct |
| James Kihara | ACAD | Common Stock | Sale | -3.56% | $22,866 | $22.20 | -1,030 | 27,865 | 07 Apr 2026 | Direct |
| Mark C. Schneyer | ACAD | Common Stock | Options Exercise | 8.75% | 5,276 | 65,545 | 05 Apr 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Restricted Stock Units | Options Exercise | -100% | -5,276 | 0 | 05 Apr 2026 | Direct | ||
| James Kihara | ACAD | Common Stock | Options Exercise | 7.48% | 2,010 | 28,895 | 05 Apr 2026 | Direct | ||
| James Kihara | ACAD | Restricted Stock Units | Options Exercise | -100% | -2,010 | 0 | 05 Apr 2026 | Direct | ||
| James Kihara | ACAD | Common Stock | Sale | -3.96% | $24,011 | $21.65 | -1,109 | 26,885 | 26 Mar 2026 | Direct |
| Mark C. Schneyer | ACAD | Common Stock | Sale | -5.05% | $69,456 | $21.65 | -3,208 | 60,269 | 26 Mar 2026 | Direct |
| Adams Catherine Owen | ACAD | Common Stock | Sale | -44% | $249,932 | $21.47 | -11,641 | 14,803 | 25 Mar 2026 | Direct |
| Elizabeth H.z. Thompson | ACAD | Common Stock | Sale | -51.2% | $73,749 | $21.47 | -3,435 | 3,280 | 25 Mar 2026 | Direct |
| Jennifer J. Rhodes | ACAD | Common Stock | Sale | -25.4% | $82,531 | $21.47 | -3,844 | 11,280 | 25 Mar 2026 | Direct |
| James Kihara | ACAD | Common Stock | Options Exercise | 8.29% | 2,142 | 27,994 | 25 Mar 2026 | Direct | ||
| James Kihara | ACAD | Common Stock | Sale | -3.12% | $17,885 | $21.47 | -833 | 25,852 | 25 Mar 2026 | Direct |
| James Kihara | ACAD | Restricted Stock Units | Options Exercise | -33.3% | -2,142 | 4,284 | 25 Mar 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Common Stock | Options Exercise | 10.8% | 6,178 | 63,477 | 25 Mar 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Common Stock | Sale | -6.79% | $89,680 | $21.47 | -4,177 | 57,299 | 25 Mar 2026 | Direct |
| Mark C. Schneyer | ACAD | Restricted Stock Units | Options Exercise | -33.3% | -6,178 | 12,358 | 25 Mar 2026 | Direct | ||
| Adams Catherine Owen | ACAD | Common Stock | Options Exercise | 801% | 23,509 | 26,444 | 24 Mar 2026 | Direct | ||
| Adams Catherine Owen | ACAD | Restricted Stock Units | Options Exercise | -25% | -23,509 | 70,530 | 24 Mar 2026 | Direct | ||
| Elizabeth H.z. Thompson | ACAD | Common Stock | Options Exercise | 6,715 | 6,715 | 24 Mar 2026 | Direct | |||
| Elizabeth H.z. Thompson | ACAD | Restricted Stock Units | Options Exercise | -25% | -6,715 | 20,146 | 24 Mar 2026 | Direct | ||
| Jennifer J. Rhodes | ACAD | Common Stock | Options Exercise | 98.8% | 7,515 | 15,124 | 24 Mar 2026 | Direct | ||
| Jennifer J. Rhodes | ACAD | Restricted Stock Units | Options Exercise | -25% | -7,515 | 22,547 | 24 Mar 2026 | Direct | ||
| James Kihara | ACAD | Common Stock | Options Exercise | 6.49% | 1,627 | 26,685 | 24 Mar 2026 | Direct | ||
| James Kihara | ACAD | Restricted Stock Units | Options Exercise | -25% | -1,627 | 4,883 | 24 Mar 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Common Stock | Options Exercise | 15.3% | 8,138 | 61,476 | 24 Mar 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Restricted Stock Units | Options Exercise | -25% | -8,138 | 24,414 | 24 Mar 2026 | Direct | ||
| James Kihara | ACAD | Restricted Stock Units | Award | 6,332 | 6,332 | 06 Mar 2026 | Direct | |||
| James Kihara | ACAD | Stock Option (Right to Buy) | Award | 21,766 | 21,766 | 06 Mar 2026 | Direct | |||
| Jennifer J. Rhodes | ACAD | Restricted Stock Units | Award | 26,382 | 26,382 | 06 Mar 2026 | Direct | |||
| Jennifer J. Rhodes | ACAD | Stock Option (Right to Buy) | Award | 90,691 | 90,691 | 06 Mar 2026 | Direct | |||
| Mark C. Schneyer | ACAD | Restricted Stock Units | Award | 26,382 | 26,382 | 06 Mar 2026 | Direct | |||
| Mark C. Schneyer | ACAD | Stock Option (Right to Buy) | Award | 90,691 | 90,691 | 06 Mar 2026 | Direct | |||
| Thomas Garner | ACAD | Restricted Stock Units | Award | 28,493 | 28,493 | 06 Mar 2026 | Direct | |||
| Thomas Garner | ACAD | Stock Option (Right to Buy) | Award | 97,947 | 97,947 | 06 Mar 2026 | Direct | |||
| Elizabeth H.z. Thompson | ACAD | Restricted Stock Units | Award | 29,548 | 29,548 | 06 Mar 2026 | Direct | |||
| Elizabeth H.z. Thompson | ACAD | Stock Option (Right to Buy) | Award | 101,574 | 101,574 | 06 Mar 2026 | Direct | |||
| Adams Catherine Owen | ACAD | Restricted Stock Units | Award | 76,509 | 76,509 | 06 Mar 2026 | Direct | |||
| Adams Catherine Owen | ACAD | Stock Option (Right to Buy) | Award | 263,005 | 263,005 | 06 Mar 2026 | Direct | |||
| Jonathan Poole | ACAD | Restricted Stock Units | Award | 6,228 | 4,218 | 03 Mar 2026 | Direct | |||
| Jonathan Poole | ACAD | Director Stock Options (Right to Buy) | Award | 11,047 | 7,482 | 03 Mar 2026 | Direct | |||
| Jennifer J. Rhodes | ACAD | Common Stock | Sale | -47.7% | $162,491 | $23.38 | -6,950 | 7,609 | 09 Feb 2026 | Direct |
| Jennifer J. Rhodes | ACAD | Common Stock | Options Exercise | 801.5% | 12,944 | 14,559 | 06 Feb 2026 | Direct | ||
| Jennifer J. Rhodes | ACAD | Restricted Stock Units | Options Exercise | -50% | -12,944 | 12,945 | 06 Feb 2026 | Direct | ||
| Mark C. Schneyer | ACAD | Common Stock | Sale | -16.1% | $243,114 | $23.69 | -10,262 | 53,338 | 18 Nov 2025 | Direct |
| James Kihara | ACAD | Common Stock | Sale | -14% | $96,754 | $23.69 | -4,084 | 25,058 | 18 Nov 2025 | Direct |
| Mark C. Schneyer | ACAD | Common Stock | Options Exercise | 45.3% | 19,826 | 63,600 | 17 Nov 2025 | Direct | ||
| Mark C. Schneyer | ACAD | Restricted Stock Units | Options Exercise | -100% | -19,826 | 0 | 17 Nov 2025 | Direct | ||
| James Kihara | ACAD | Common Stock | Options Exercise | 37.4% | 7,932 | 29,142 | 17 Nov 2025 | Direct | ||
| James Kihara | ACAD | Restricted Stock Units | Options Exercise | -100% | -7,932 | 0 | 17 Nov 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.